Markers of Arterial Stiffness Are Risk Factors for Progression to End-Stage Renal Disease among Patients with Chronic Kidney Disease Stages 4 and 5
Authors:
- Maarten W. TaalMTMaarten W. Taal
- Mhairi K. SigristMSMhairi K. Sigrist
- Apostolos FakisAFApostolos Fakis
- Richard J. FluckRFRichard J. Fluck
- Christopher W. McIntyreCMChristopher W. McIntyre
- 1 November 2007
- journal article
- Published by S. Karger AG in Nephron Clinical Practice
- Vol. 107 (4) , c177-c181
Abstract
Background: Factors associated with chronic kidney disease (CKD) contribute to an increased risk of cardiovascular disease and death. The impact of vascular disease on CKD progression is, however, less well studied. Methods: We examined the effect of markers of vascular disease on the risk of progression to end-stage renal disease (ESRD) in 35 patients with CKD stages 4–5. Superficial femoral artery calcification was assessed by CT scan. Augmentation index (AI) and pulse wave velocity (PWV) were measured by applanation tonometry. Results: After 12.4 (5.5–28.4) months, 22/35 patients (63%) had commenced dialysis. Cox regression analysis identified baseline estimated glomerular filtration rate (hazard ratio, HR, 0.54; 95% CI 0.41–0.70; p < 0.0001), urinary protein (HR 1.84; 95% CI 1.32–2.58; p = 0.0005), PWV (HR 1.30; 95% CI 1.07–1.60; p = 0.01), AI (HR 1.08; 95% CI 1.04–1.14; p = 0.0001) and pack years of smoking (HR 1.01; 95% CI 1.00–1.03; p = 0.02) as independent risk factors for time to ESRD (–2 log likelihood = 86.7; χ2 = 30.9; p < 0.0001). Repeat analysis using AI as a categorical variable revealed an HR of 17.5 (95% CI 4.43–68.9; p < 0.0001) for time to ESRD in those with AI above versus below the median. Conclusions: We have identified two markers of arterial stiffness as independent risk factors for progression to ESRD suggesting that vascular disease may contribute to CKD progression.Keywords
This publication has 8 references indexed in Scilit:
- High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resectionHuman Pathology, 2009
- The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signalingOncogene, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Norepinephrine-mediated Regulation of 5HT1 Receptor Functioning in Human PlateletsNeurochemical Research, 2008
- Cell Density–Dependent Increase of Constitutive Signal Transducers and Activators of Transcription 3 Activity in Melanoma Cells Is Mediated by Janus KinasesMolecular Cancer Research, 2007
- Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancerBreast Cancer Research, 2007
- Deletion of the SOCS3 Gene in Liver Parenchymal Cells Promotes Hepatitis–Induced HepatocarcinogenesisGastroenterology, 2006
- Distinct Role of Macrophages in Different Tumor MicroenvironmentsCancer Research, 2006